Beaton Management Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.25M Sell
10,366
-49
-0.5% -$10.9K 1% 34
2025
Q4
$2.38M Sell
10,415
-13
-0.1% -$2.96K 1.05% 31
2025
Q3
$2.42M Buy
10,428
+1
+0% +$204 1.1% 31
2025
Q2
$1.94M Buy
10,427
+77
+0.7% +$14.3K 0.95% 31
2025
Q1
$2.17M Sell
10,350
-200
-2% -$38.9K 1.13% 28
2024
Q4
$1.88M Buy
10,550
+116
+1% +$21.3K 0.95% 31
2024
Q3
$2.06M Sell
10,434
-499
-5% -$93.1K 1.04% 30
2024
Q2
$1.88M Buy
10,933
+48
+0.4% +$7.95K 1.01% 29
2024
Q1
$1.98M Buy
10,885
+52
+0.5% +$8.96K 1.08% 28
2023
Q4
$1.68M Sell
10,833
-65
-0.6% -$9.48K 1.01% 31
2023
Q3
$1.63M Buy
10,898
+41
+0.4% +$6.02K 1.06% 30
2023
Q2
$1.46M Buy
10,857
+238
+2% +$34.9K 0.93% 34
2023
Q1
$1.69M Sell
10,619
-99
-0.9% -$15.1K 1.14% 29
2022
Q4
$1.73M Buy
10,718
+2
+0% +$307 1.16% 28
2022
Q3
$1.44M Sell
10,716
-124
-1% -$17.8K 1.09% 30
2022
Q2
$1.66M Sell
10,840
-164
-1% -$25.1K 1.18% 28
2022
Q1
$1.78M Buy
11,004
+3
+0% +$436 1.1% 27
2021
Q4
$1.49M Hold
11,001
0.89% 38
2021
Q3
$1.19M Buy
11,001
+100
+0.9% +$11.4K 0.79% 39
2021
Q2
$1.23M Sell
10,901
-200
-2% -$22.5K 0.78% 45
2021
Q1
$1.2M Buy
11,101
+1,774
+19% +$190K 0.83% 41
2020
Q4
$999K Buy
9,327
+100
+1% +$9.61K 0.74% 44
2020
Q3
$808K Sell
9,227
-535
-5% -$50.4K 0.67% 52
2020
Q2
$958K Buy
9,762
+1,777
+22% +$156K 0.85% 42
2020
Q1
$608K Buy
7,985
+325
+4% +$27.7K 0.61% 58
2019
Q4
$678K Buy
7,660
+300
+4% +$24.9K 0.53% 57
2019
Q3
$557K Buy
7,360
+200
+3% +$13.7K 0.45% 66
2019
Q2
$521K Buy
7,160
+250
+4% +$19.6K 0.43% 69
2019
Q1
$557K Hold
6,910
0.48% 64
2018
Q4
$637K Hold
6,910
0.63% 54
2018
Q3
$654K Hold
6,910
0.54% 55
2018
Q2
$640K Hold
6,910
0.57% 56
2018
Q1
$654K Hold
6,910
0.6% 54
2017
Q4
$668K Sell
6,910
-366
-5% -$34.5K 0.6% 56
2017
Q3
$647K Hold
7,276
0.61% 55
2017
Q2
$528K Buy
+7,276
New +$489K 0.52% 59

Other funds holding ABBV

Beaton Management Company's ABBV Position: Q1 2026 in Review

Beaton Management Company reduced its AbbVie (ABBV) stake by 0.47% in Q1 2026, selling an estimated $10.9K and leaving 10,366 shares worth $2.25M. The position accounts for 1% of the portfolio, ranked #34.

Beaton Management Company first reported a position in ABBV in Q2 2017 and has held it in 36 quarters since. The position peaked at $2.42M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Beaton Management Company held 10,366 shares of AbbVie worth $2.25M as of Q1 2026.
  • Beaton Management Company sold 49 AbbVie shares in Q1 2026, an estimated $10.9K.
  • AbbVie made up 1% of Beaton Management Company's portfolio in Q1 2026, its #34 holding.
  • Beaton Management Company first reported a position in AbbVie in Q2 2017 and has held it in 36 quarters since.
  • Beaton Management Company's AbbVie position peaked at $2.42M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Beaton Management Company's 13F filing for Q1 2026, filed 12 May 2026.